4.7 Review

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.730400

关键词

SHP-1; SHP-2; SHIP; leukemia; AML; PTP inhibitor; signaling pathway; thrapeutic target

资金

  1. AHA [9CDA34770036]
  2. NIH [R37CA241603]

向作者/读者索取更多资源

Protein tyrosine phosphatases play a crucial role in modulating cellular functions and have been linked to human leukemia; however, the impact of these phosphatases and their mutations on leukemia remains controversial.
Protein tyrosine phosphatases (PTPs) are modulators of cellular functions such as differentiation, metabolism, migration, and survival. PTPs antagonize tyrosine kinases by removing phosphate moieties from molecular signaling residues, thus inhibiting signal transduction. Two PTPs, SHP-1 and SHP-2 (SH2 domain-containing phosphatases 1 and 2, respectively) and another inhibitory phosphatase, SH2 domain-containing inositol phosphatase (SHIP), are essential for cell function, which is reflected in the defective phenotype of mutant mice. Interestingly, SHP-1, SHP-2, and SHIP mutations are identified in many cases of human leukemia. However, the impact of these phosphatases and their mutations regarding the onset and progression of leukemia is controversial. The ambiguity of the role of these phosphatases imposes challenges on the development of targeting therapies for leukemia. This fundamental problem, confronted by the expanding investigational field of leukemia, will be addressed in this review, which will include a discussion of the molecular mechanisms of SHP-1, SHP-2, and SHIP in normal hematopoiesis and their role in leukemia. Clinical development of leukemic therapies achieved by targeting these phosphatases will be addressed as well.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据